CoChat

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies

Open access
Baldwin, David S, Chrones, Lambros, Florea, Ioana, Nielsen, Rebecca, Nomikos, George G, Palo, William, Reines, Elin · 2016 · Journal of Psychopharmacology
Cited by 187

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on the nature, incidence and severity of treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment in 11 randomized, double-blind placebo-controlled short-term studies in major depressive disorder: six with an active reference. Symptoms following discontinuation were assessed through the Discontinuation-Emergent Signs and Symptoms checklist in three studies. Long-term (⩽52 weeks) tolerability was evaluated in five open-label extension studies. Patients ( n =5701) were acutely treated with either placebo ( n=1817), vortioxetine (5–20mg/day; n=3018), venlafaxine XR (225mg/day; n=113) or duloxetine (60mg/day; n=753). The withdrawal rate due to TEAEs during treatment with vortioxetine (5–20mg/day) was 4.5–7.8%, compared with placebo (3.6%), venlafaxine XR (14.2%) or duloxetine (8.8%). Common TEAEs (incidence ⩾5% and >2 × placebo) with vortioxetine (5–20mg/day) were nausea (20.9–31.2%) and vomiting (2.9–6.5%). For vortioxetine (5–20mg/day), the incidence of TEAEs associated with insomnia was 2.0–5.1% versus 4.0% for placebo, and with sexual dysfunction 1.6–1.8% versus 1.0% for placebo. Discontinuation symptoms as assessed by the mean Discontinuation-Emergent Signs and Symptoms total score after abrupt discontinuation were comparable to placebo in the first and second week. Vortioxetine had no effect relative to placebo on clinical laboratory parameters, body weight, heart rate or blood pressure. Vortioxetine showed no clinically relevant effect on ECG parameters, including the QTcF interval. In long-term treatment, no new types of TEAEs were seen; the mean weight gain was 0.7–0.8kg. Thus, vortioxetine (5–20mg/day) appears safe and generally well tolerated in the treatment of major depressive disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0269881116628440

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 26

  1. 10.1097/YIC.0000000000000010 · DOI · Paper page
  2. 10.1111/bcpt.12256 · DOI
  3. 10.1185/03007995.2012.725035 · DOI · Paper page
  4. 10.1016/j.euroneuro.2011.11.008 · DOI
  5. 10.1016/j.euroneuro.2012.07.012 · DOI
  6. 10.1007/s40261-013-0117-6 · DOI · Paper page
  7. Chen G, 2012, Clin Pharm Ther, 91, S39, 10.1038/clpt.2012.27 · DOI
  8. Chen G, 2011, J Clin Pharmacol, 51, 1350, 10.1177/0091270010368411 · doi:10.1177/0091270010368411
  9. 10.1002/jcph.456 · DOI
  10. 10.1111/ijcp.12350 · DOI · Paper page
  11. 10.1016/S0924-977X(13)70510-8 · doi:10.1016/s0924-977x(13)70510-8
  12. 10.1016/S0924-977X(12)70383-8 · DOI
  13. 10.1124/dmd.112.044610 · DOI
  14. 10.1097/YIC.0000000000000081 · DOI · Paper page
  15. 10.1111/jsm.12980 · DOI · Paper page
  16. 10.4088/JCP.14m09335 · DOI · Paper page
  17. 10.1185/03007995.2012.761600 · DOI · Paper page
  18. 10.1111/ijcp.12328 · DOI · Paper page
  19. 10.1002/hup.2371 · DOI · Paper page
  20. Mayer M, 2012, Clin Pharmacol Drug Dev, 1, 188
  21. 10.1016/S0006-3223(98)00126-7 · DOI · Paper page
  22. 10.1016/j.euroneuro.2012.07.011 · DOI
  23. 10.1038/clpt.2013.39 · DOI · Paper page
  24. Wang Y, 2011, Clin Pharm Ther, 89, S71
  25. 10.1002/cpdd.51 · DOI
  26. 10.1177/0269881115599387 · DOI · Paper page

Cited by

See all 187

Metadata

Authors
Baldwin, D. S., Chrones, L., Florea, I., Nielsen, R., Nomikos, G. G., Palo, W., & Reines, E.
Venue
Journal of Psychopharmacology
Published
2016-02-09
Volume
30
Issue
3
Pages
242-252
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2270496518
Cited by
187
References
12
FWCI
9.99
Type
journal article
Language
en
Open access
hybrid
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. https://app.cochat.ai/papers/10.1177/0269881116628440
The paper
Baldwin, D. S., Chrones, L., Florea, I., Nielsen, R., Nomikos, G. G., Palo, W., & Reines, E. (2016). The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116628440

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.